Study of daratumumab with EPOCH for plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have plasmablastic lymphoma confirmed by biopsy/pathology and appropriate lab markers.
- Your lymphoma is stage II–IV, or stage I but with a high LDH level or a bulky tumor.
- You have measurable tumor on scan (at least 1.5 cm) or disease found in bone marrow.
- Your general health is strong enough for chemotherapy (ECOG 0–2) and key blood counts and organ labs are within limits.
- If you have HIV, your CD4 count is at least 100, you can’t have certain serious past infections in the last year, and you must be on HIV treatment (or start it).
- You can’t be pregnant or breastfeeding, and you must use reliable birth control during treatment and for 3 months after daratumumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This study tests an investigational drug called elranatamab to see if it can help keep plasmablastic lymphoma from coming back after you've finished your first treatment. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This trial tests a new drug called glofitamab combined with standard chemoimmunotherapy (called R-CHOP) for people with HIV-related large B-cell lymphoma that has not been treated before. The goal is to see if adding this drug improves outcomes and is safe.
This trial tests a drug called daratumumab for people with certain HIV-related blood cancers (primary effusion lymphoma, plasmablastic lymphoma) or a related condition called multicentric Castleman disease that has come back or not improved after standard treatment. The drug targets a protein on cancer cells to help the immune system attack them. It might be a new option when standard chemotherapy isn't working or isn't suitable.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.